Targretin (bexarotene) 75mg capsules
Mfg by: R.P. Scherer for: Ligand Pharmaceuticals Inc.
Indication(s): Treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy.
Administration: A single oral daily dose with a meal. Initial dose is 300mg/m2/day.
Pharmacology: Bexarotene selectively binds and activates retinoid X receptor subtypes (RXRalpha, RXRßeta, RXRgamma).
WebRx Editorial Notes: Pregnancy category X (must NOT be given to a pregnant woman). Although no formal drug interaction studies have been performed with bexarotene it is known that the drug is metabolized by cytochrome P450 3A4. Inhibitors of cyt-P450 3A4 such as ketoconazole, itraconazole, erythromycin, gemfibrozil, and grapefruit juice would be expected to increase levels of bexarotene. Inducers of cyt-P450 3A4 such as rifampin, phenytoin, phenobarbital, and others would be expected to reduce levels of bexarotene.
This drug should not be used as a first-line agent. The side effect profile is extensive including dose-dependent lipid abnormalities, hypothyroidism, rash, leukopenia, nausea, peripheral edema, headache, asthenia (loss of strength), and infection as major sequalae.
©2000, 2001 WebRx Pharmacy Palace